Palo Santo

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.

Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.

Founded in 2019, Ksana Health specializes in digital mental health solutions. Its platform collects user data related to mental health and facilitates its transfer to healthcare practitioners for improved patient care.

Eleusis is a clinical stage life science company focused on harnessing the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics. The company aims to develop innovative psychedelic drug therapies that address unmet medical needs, particularly in the field of psychiatry and beyond. Eleusis is advancing a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. By doing so, the company seeks to provide healthcare providers and pharmaceutical companies with viable alternatives to conventional therapies, thereby broadening the scope of treatment options available to patients.